abstracts

P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice

BACKGROUND: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that is a life-long condition with a relapsing and remitting course. As with other chronic diseases,...

12/15/2021

P010 Precision Dosing Tool Forecasts Trough Infliximab and Associates With Disease Status in Inflammatory Bowel Diseases

BACKGROUND: Substantial inter- and intra-individual variability of infliximab (IFX) pharmacokinetics (PK) necessitates tailored dosing approaches. Here, we evaluated the perfo...

12/15/2021

P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay

BACKGROUND: The prevalence of cannabis use has been increasing in the United States in recent years. We examined the prevalence and predictors of cannabis use disorder among I...

12/15/2021

P036 Disparities in Diagnosis and Management of Patients with Crohn’s Perianal Fistulas: Results of a US National Patient and Caregiver Survey

BACKGROUND: Crohn’s perianal fistulas (CPF) contribute to lowered quality of life for patients with Crohn’s disease. Previous research has indicated potential racial and/or et...

12/15/2021

P012 Efficacy of Exclusive Enteral Nutrition and Weekly Adalimumab Combination in Crohn's Patients With Fibroinflammatory Stenosis

BACKGROUND: Clinical remission can be achieved with exclusive enteral nutrition (EEN) in patients with Crohn's Disease with different sites of involvement, varying severity, a...

12/15/2021

P002 Psychiatric Comorbidity and Suicide in Childhood Onset Immune-Mediated Diseases —A Systematic Review and Meta-Analysis

BACKGROUND: The course of paediatric onset immune mediated inflammatory diseases (IMID) is both physically and mentally challenging. Emotional distress with anxiety and depres...

12/15/2021

P013 Resolution of Infliximab Associated Infusion Hypersensitivity After Switching to Biosimilar Infliximab-dyyb

CASE: Background: Administration of infliximab for the treatment of inflammatory bowel disease has a well-recognized risk of infusion-related (IR) adverse events. The recent i...

12/15/2021

P012 Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study

Ghosh Subrata1, D’Haens Geert2, Jairath Vipul3, Rieder Florian4, Petersen AnnKatrin5, Usiskin Keith5, Chitkara Denesh5, Colombel Jean-Frederic6

12/10/2020

P011 Physical activity levels in daily life of patients with moderate-to-severe Crohn’s disease before and after Infliximab-induced remission

Chebli Julio1, Chebli Liliana1, Lucca Fernando2, Malaguti Carla2, Oliveira Isaac1, Gaburri Pedro2, Ribeiro Tarsila1 1 Federal University of Juiz de Fora, Juiz de Fora, Brazil, 2 UFJF, ...

12/10/2020

P002 Frequency and causes of prolongation of the induction course of tofacitinib in patients with ulcerative colitis.

Knyazev Oleg1, Kagramanova Anna1, Lishchinskaya Albina1, Shkurko Tatyana2, Zvyaglova Mariya1, Kulakov Dmitriy1, Demchenko Alexandra1 1 Moscow Clinical Scientific Center named after A. S....

12/10/2020

abstracts

Follow Us on Twitter!

Specialties

Events

Year Round Education

HMP Global Products